Medicenna Therapeutics (TSE:MDNA) has released an update.
Medicenna Therapeutics is set to present promising updates on its MDNA11 ABILITY-1 trial, showcasing anti-tumor activity and safety data, at the American Association for Cancer Research Annual Meeting. The company will also reveal pre-clinical findings for MDNA113, a novel tumor-targeted Superkine, during the prestigious conference. These developments highlight Medicenna’s commitment to advancing cancer immunotherapy with its innovative Superkine platform.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
